naltrexone azine | 91796-68-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: naltrexone azine
• 英文别名: Naltrexonazine；(4R,4aS,7E,7aR,12bS)-7-[(E)-[(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ylidene]hydrazinylidene]-3-(cyclopropylmethyl)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
• CAS: 91796-68-8
• 化学式: C₄₀H₄₆N₄O₆
• 分子量: 678.828
• InChiKey: GSYDZKZBXPTRGD-QWLHVPTFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  50
• 可旋转键数：
  5
• 环数：
  12.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  131
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  盐酸纳曲酮 在 盐酸肼 作用下， 以 甲醇 为溶剂， 反应 0.58h， 以87%的产率得到naltrexone azine
  参考文献：
  名称：

  X-ray crystal structure of the opioid ligand naltrexonazine

  摘要：

  The anti-anti isomer of naltrexonazine (1) was synthesized, and its configuration was confirmed by X-ray crystallography. The syn-anti isomer is readily converted to 1 under acidic conditions. The apparent equal receptor binding of 1 and syn-anti isomer indicates that isomerization of the azine moiety may take place under the conditions of biological evaluation. Two possible explanations for wash-resistant binding of 1 to opioid receptors are presented. The first possibility involves a noncovalent interaction of the ligand with the opioid receptor, and the second considers covalent binding by a receptor-based sulfhydryl group.

  DOI：

  10.1021/jm00391a035

文献信息

• Methods for the chemical synthesis of pyrrole-linked bivalent compounds, and compositions thereof
  申请人：AVEKSHAN LLC

  公开号：US10253034B2

  公开（公告）日：2019-04-09

  The present invention in various aspects relates to the synthesis of pyrrole-linked bivalent compounds, including but not limited to norBNI, as well as pharmaceutical compositions comprising the same.

  本发明在多个方面涉及吡咯连接的二价化合物的合成，包括但不限于 norBNI 以及包含这些化合物的药物组合物。
• METHODS FOR THE CHEMICAL SYNTHESIS OF PYRROLE-LINKED BIVALENT COMPOUNDS, AND COMPOSITIONS THEREOF
  申请人：AVEKSHAN LLC

  公开号：US20180072747A1

  公开（公告）日：2018-03-15

  The present invention in various aspects relates to the synthesis of pyrrole-linked bivalent compounds, including but not limited to norBNI, as well as pharmaceutical compositions comprising the same.